Barry J Byrne, MD, PhD, on MDA Care Centers and the Upcoming Clinical & Scientific Conference

Commentary
Video

The chief medical advisor of the Muscular Dystrophy Association discussed what seasoned clinicians and newcomers to the field alike can look forward to at the 2024 MDA Meeting.

“There are many missions of the Muscular Dystrophy Association: Both excellence in patient care and advancing multidisciplinary care, as well as assisting in discovering new therapies that improve the lives of those living with neuromuscular diseases.”

The Muscular Dystrophy Association (MDA) is an organization dedicated to serving the community of patients with neuromuscular disorders, both those with muscular dystrophies and those with other types of neuromuscular disease. A key way that the MDA has pursued this mission is through the establishment of over 150 MDA Care Centers throughout the United States. These centers serve as both centers of primary care for patients with neuromuscular diseases and as a network of research hubs for experts in the field to collaborate. The organization also annually hosts the MDA Clinical & Scientific Conference, an event that brings together both practicing clinicians and medical researchers under one roof to discuss and share ongoing research in the field.

Ahead of the 2024 meeting, which will be held on March 3-6, 2024, in Orlando, Florida, CGTLive™ spoke with Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida, to learn more about both MDA Care Centers and the upcoming conference. Byrne spoke about the goals of the organization and its activities in general, including the role of the Care Centers, and then spoke about the reasons why doctors and other healthcare professionals with an interest in neuromuscular diseases may want to attend the Clinical & Scientific Conference. He also highlighted what he is most excited about for the 2024 meeting in particular, emphasizing that attendees will be working on establishing a Gene Therapy Readiness Network. Byrne concluded the interview by encouraging early-career trainees in medicine to attend the conference, pointing out that they can benefit greatly from the firsthand chance to learn about the opportunities in neuromuscular disease care.

Click here to register for the upcoming 2024 MDA Conference.

Recent Videos
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Lucas Harrington, PhD, the cofounder and chief scientific officer of Mammoth Biosciences
Stephanie Tagliatela on Researching AAV for Lennox-Gastaut, Alzheimer Disease, SCN9a Pain
Miloš Miljković, MD, on mRNA-CAR-T Descartes-08's Potential for Treating Myasthenia Gravis
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Related Content
© 2024 MJH Life Sciences

All rights reserved.